SG/CALL/ROCHE GS/340/0.1/20.09.24 Stock

Warrant

DE000SW13PH7

Market Closed - Deutsche Boerse AG 15:50:16 2024-05-21 EDT
0.024 EUR -7.69% Intraday chart for SG/CALL/ROCHE GS/340/0.1/20.09.24
Current month+136.36%
1 month-7.14%
Date Price Change
24-05-21 0.024 -7.69%
24-05-20 0.026 -7.14%
24-05-17 0.028 -50.00%
24-05-16 0.056 +366.67%
24-05-15 0.012 +71.43%

Delayed Quote Deutsche Boerse AG

Last update May 21, 2024 at 03:50 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Société Générale Société Générale
WKN SW13PH
ISINDE000SW13PH7
Date issued 2023-08-10
Strike 340 CHF
Maturity 2024-09-20 (122 Days)
Parity 10 : 1
Emission price 0.41
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.35
Lowest since issue 0.001
Spread 0.073
Spread %75.26%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
234.4 CHF
Average target price
279.4 CHF
Spread / Average Target
+19.19%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW